Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]
News [3678]
Articles [22]
Editorials [1]
Conferences [135]
elearning [0]
Comment on RESONATE2 and CLL115 trials
Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK
Comment on RESONATE2 and CLL115 trials ( Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )
29 Apr 2016
Clinical cases employing novel agents in Hodgkin lymphoma
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA
Clinical cases employing novel agents in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA )
29 Apr 2016
Current trials in chronic lymphocytic leukaemia
Dr George Follows - Cambridge University Hospitals NHS Foundation Trust...
Current trials in chronic lymphocytic leukaemia ( Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )
29 Apr 2016
Chronic lymphocytic leukaemia: Transition to a new era
Prof Stephen Mulligan - Royal North Shore Hospital, Australia
Chronic lymphocytic leukaemia: Transition to a new era ( Prof Stephen Mulligan - Royal North Shore Hospital, Australia )
29 Apr 2016
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL
Prof Jan Burger, MD Anderson Cancer Center, Texas, USA
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL ( Prof Jan Burger, MD Anderson Cancer Center, Texas, USA )
29 Apr 2016
The role of the microenvironment and novel therapies in CLL
Prof Jan Burger - MD Anderson Cancer Center, Texas, USA
The role of the microenvironment and novel therapies in CLL ( Prof Jan Burger - MD Anderson Cancer Center, Texas, USA )
29 Apr 2016
Editor's Choice for April 2016
Prof Gordon McVie - ecancer Editor
Editor's Choice for April 2016 ( Prof Gordon McVie - ecancer Editor )
29 Apr 2016
Drugging “undruggable” transcription factor drivers in cancer
Dr John Bushweller - Unviersity of Virgina, Virginia, USA
Drugging “undruggable” transcription factor drivers in cancer ( Dr John Bushweller - Unviersity of Virgina, Virginia, USA )
28 Apr 2016
Pembrolizumab yielded durable responses in patients with advanced Merkel cell...
Dr Paul Nghiem - University of Washington, Seattle, USA
Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma ( Dr Paul Nghiem - University of Washington, Seattle, USA )
28 Apr 2016
Combination therapy before surgery improves outcomes for patients with HER2...
Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania...
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )
28 Apr 2016
Elucidation and pharmacological targeting of tumour checkpoint dependencies
Dr Andrea Califano - Colombia University Medical Centre, New York, USA
Elucidation and pharmacological targeting of tumour checkpoint dependencies ( Dr Andrea Califano - Colombia University Medical Centre, New York, USA )
28 Apr 2016
Identifying myeloid-driven biologies
Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA
Identifying myeloid-driven biologies ( Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA )
28 Apr 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation